Submit An Article

cancer treatment

Home
cancer treatment

Most Read
Latest Comments

Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
- Review
- January 10, 2023
Opening a new frontier in treating Parkinson’s disease
- Review
- November 11, 2022
AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
- Review
- June 9, 2022
PharmAust completes dosing first cohort for MND treatment, patients respond positively
- Review
- January 6, 2023
Is this the most hated company on the ASX?
- Review
- August 16, 2019

Latest Articles

- Opinion
Small Caps Watch: Pharmaxis CEO Gary Phillips
Sitting down with Gary Phillips reminds me of chatting to my favourite chemistry teacher in high school. Not that you’d usually compare a biotech company CEO to a past teacher but much like Mr McLeod, Gary has the unique ability to get you excited about science. Gary heads up Pharmaxis (ASX: PXS), a Sydney-based biotechnologyRead More
Public
- News
Noxopharm achieves significant pain relief for late-stage prostate cancer patients
Prostate cancer patients could soon be in for potentially good news after clinical stage-drug development company, Noxopharm (ASX: NOX) reported interim data indicating effective anti-cancer responses from patients receiving treatment for late-stage prostate cancer. To date, the data from the study (DARRT-1) found that 80% of patients showed no further progression in their disease after
Read More
Public
- News
Immutep clinical trials deliver significant tumour shrinkage in late-stage cancer patients
Australian biotech company Immutep (ASX: IMM, NASDAQ: IMMP) has delivered impressive Phase I clinical trial results for its TACTI-mel trial which has observed significant tumour size shrinkage in the majority of trial patients over the 12 month trial period. The trials tested 24 patients with melanoma which were located in areas not capable of being
Read More
Public

1
2

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.